Despite these mixed results, the potential of GLP-1 RAs to modulate key pathways involved in HF, such as inflammation, endothelial function, and atherosclerosis, positions them as valuable tools in the broader management of cardiovascular risk in insulin-resistant patients [147,148,149]. This evidence concerns the gene GCG and hydrops fetalis.